�The administration of therapeutic drugs via injection is an indispensable delivery method for legion drugs critical to patient health and well-being. Now this segment is evolving in reception to ever-changing patient populations, new classes of powerful therapeutic drugs, and healthcare administration initiatives. Population demographics and efforts by managed care providers to control healthcare costs are driving the growth in drug self-administration, peculiarly for chronic conditions, introducing a modern class of na�ve users to parenteral drug delivery. User-friendly syringe and shot device designs and the availability of an increasing number of drugs in pre-filled insertable and disposable cartridges are propelling the growth of prefilled syringes for self-administration.
Improved patient compliance, efficient delivery of high-priced biologicals, and patient & caregiver safety are key market drivers in this sector. The cost of biologicals such as recombinant proteins has created interest in prefilled syringes to reduce cost and waste associated with the handling and overfilling of vial-packaged drugs. Partnerships between device designers and do drugs developers are an essential element in the winner of prefilled devices, in particular for patient self-administration.
Leading prefilled syringe applications include chronic diseases such as diabetes, autoimmune disorders, and endocrine replacement. Other growth segments include reproductive health and the administration of antivirals, as well as health programs and vaccine administration.
These findings ar contained in a new and comprehensive report: Prefilled Syringes: Drugs, Devices and Disease Therapeutics.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and applied science and market place assessment.
Greystone Associates
More info
